Skip to main content

Treatment Clinical Trials for Pancreatic Cancer

Review the pancreatic cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 202

Gemcitabine, Cisplatin, and Nab-Paclitaxel in Combination with Tumor Treatment Fields for the Treatment of Recurrent and/or Metastatic Pancreatic Cancer
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Gemcitabine and Leflunomide in Patients with Advanced Unresectable Pancreatic Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Intraperitoneal Paclitaxel with NALIRIFOX for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Ductal Adenocarcinoma with Peritoneal Carcinomatosis
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Zunsemetinib with mFOLFIRINOX for the Treatment of Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Chimeric Antigen Receptor (CAR) T-cell Therapy with iC9-CAR.B7-H3 T-cells for the Treatment of Refractory Pancreatic Ductal Adenocarcinoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
CBP-1019 with FOLFOX with or without Bevacizumab, Pembrolizumab, or Enzalutamide for the Treatment of Metastatic Solid Tumors of Epithelial Origin
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Status: Active
Location: 2 locations
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adagrasib in Combination with Olaparib for the Treatment of KRAS G12C Mutated Advanced Solid Tumors with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Status: Active
Location: 2 locations
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Adaptive Radiation Therapy for the Treatment of Locally Advanced Unresectable Pancreatic Cancer
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: See ClinicalTrials.gov
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Status: Active
Location: See ClinicalTrials.gov